Strauss Borrelli PLLC, a leading data breach law firm, is investigating Syndax Pharmaceuticals, Inc. (“Syndax”) regarding its recent data breach. The Syndax data breach involved sensitive personal identifiable information belonging to an undetermined number of individuals.
ABOUT SYNDAX PHARMACEUTICALS, INC.:
Syndax is a biotechnology research and pharmaceutical company based in Massachusetts. Founded in 2005, Syndax is a clinical stage oncology innovator developing first-in-class therapies for acute leukemias and chronic graft-versus-host disease.2 With a steadfast commitment to its mission of obtaining regulatory approval and commercializing drugs that extend and improve the lives of cancer patients, Syndax is an oncology leader advancing differentiated and targeted cancer therapies.2 Headquartered in Waltham, Massachusetts, Syndax employs over 50 individuals.
WHAT HAPPENED?
Recently, Syndax discovered that it had experienced a data breach in which sensitive personal identifiable information in its systems may have been accessed. Through its investigation, Syndax determined that an unauthorized party may have accessed this sensitive information on or about January 29, 2024. On February 22, 2024, Syndax began notifying individuals whose information may have been impacted. The type of information potentially exposed includes:
- Name
- Social Security number
- Address
If you received a breach notification letter from Syndax Pharmaceuticals, Inc.:
We would like to speak with you about your rights and potential legal remedies in response to this data breach. Please fill out the form, below, or contact us at 872.263.1100 or sam@straussborrelli.com.
